ICD-10 Coding for Descovy (Emtricitabine/Tenofovir Alafenamide)
Use ICD-10 code Z20.6 (Contact with and [suspected] exposure to HIV) for prescribing Descovy for HIV pre-exposure prophylaxis (PrEP), as this is the most appropriate existing code for documenting HIV prevention services in clinical practice.
Primary ICD-10 Code for PrEP
The code Z20.6 is the standard billing code for PrEP prescriptions because it documents exposure risk to HIV, which is the clinical justification for prescribing antiretroviral prophylaxis 1. This code allows insurance authorization and tracks preventive HIV services in administrative databases.
Alternative Supporting Codes
Depending on your specific clinical scenario, you may also consider:
- Z72.52 (High-risk homosexual behavior) - for men who have sex with men
- Z72.53 (High-risk bisexual behavior) - for bisexual individuals
- Z20.2 (Contact with and [suspected] exposure to infections with a predominantly sexual mode of transmission) - for broader STI exposure documentation
- Z29.81 (Encounter for HIV pre-exposure prophylaxis) - though this code is underutilized in practice (only 0.3% of encounters) 2
Important Clinical Context
Before prescribing Descovy, you must document:
- Negative HIV antibody/antigen test immediately before starting 3, 1
- Calculated creatinine clearance ≥60 mL/min 3
- Hepatitis B surface antigen status 1
Common pitfall: The evidence shows that most encounters for PrEP-eligible patients use Z20.2 (78.2% of cases) rather than more specific codes, and doxycycline prescriptions (a parallel situation) demonstrate that existing ICD-10 codes inadequately capture prevention services 2. However, Z20.6 remains your best option until a dedicated PrEP code is created.
Descovy-Specific Considerations
Descovy (emtricitabine/tenofovir alafenamide) is FDA-approved for both HIV treatment and PrEP 4. The 200 mg/25 mg formulation is standard for adults 4, while the 120 mg/15 mg formulation is for pediatric patients 4.
For PrEP specifically: Tenofovir alafenamide/emtricitabine (TAF/FTC, the components of Descovy) is recommended for men who have sex with men with or at risk for kidney dysfunction, osteopenia, or osteoporosis 1. The 2025 CDC guidelines list bictegravir/emtricitabine/tenofovir alafenamide as a preferred regimen for post-exposure prophylaxis 5, demonstrating the clinical acceptance of TAF-based regimens.
Documentation Strategy
When ordering Descovy for PrEP:
- Use Z20.6 as your primary diagnosis code
- Add behavioral risk codes (Z72.52 or Z72.53) as secondary codes if applicable
- Document the negative HIV test result in the medical record
- Note creatinine clearance calculation
- Include any specific risk factors (e.g., HIV-positive partner, high-risk sexual behavior)
This approach ensures insurance coverage while creating an auditable trail for quality metrics and public health surveillance.